*  Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist -Pipeline Insight, 2018
Receptor (LHRH Receptor) Antagonist. • Features the Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist ... Receptor (LHRH Receptor) Antagonist. The report assesses the active Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH ... Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist -Pipeline Insight, 2018. *January 2018 • ... "Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist - Pipeline Insight, 2018" report by DelveInsight ...
  https://www.reportbuyer.com/product/5129607/gonadotropin-releasing-hormone-gnrh-receptor-lhrh-receptor-antagonist-pipeline-insight-2018.html
*  Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action | Science
Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action ... Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action ... Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action ... Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action ...
  http://science.sciencemag.org/content/216/4544/420
*  Amiloride derivatives and a non-peptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing...
... and a non-peptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Laura ... and a non-peptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Laura ... and a non-peptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Laura ... and a non-peptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor ...
  http://molpharm.aspetjournals.org/content/early/2008/03/14/mol.107.043521
*  Patent US6319931 - Use of a compound with affinity for the mitochondrial benzodiazepine ... - Google Patents
... to a combination product comprising at least one compound with affinity for the mitochondrial benzodiazepine receptor, and to ... Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. US20100184741 *. 4 Apr 2008. 22 Jul 2010. ... Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. US20110212959 *. 7 Mar 2011. 1 Sep 2011. ... Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. US8088759. 1 Nov 2006. 3 Jan 2012. The ...
  http://www.google.com.au/patents/US6319931
*  Degarelix New FDA Drug Approval | CenterWatch
Degarelix is a Gonadotropin-releasing hormone (GnRH) receptor antagonist. It binds reversibly to the pituitary GnRH receptors, ... Degarelix is a Gonadotropin-releasing hormone (GnRH) receptor antagonist. It binds reversibly to the pituitary GnRH receptors, ... a new gonadotropin-releasing hormone antagonist. The Journal of Pharmacology and Experimental Therapeutics 2007 Mar;320(3):1113 ... and long-acting gonadotropin-releasing hormone antagonist: degarelix. The Journal of Pharmacology and Experimental Therapeutics ...
  https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1010/degarelix-degarelix-for-injection
*  Patents filed at Nov 01 2016 | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell...
Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical.... Disclosed are a ... gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in ... A dual H1/5-HT.sub.2A receptor antagonist of the formula: ##STR00001## its uses, and methods for its preparation are described ... Androgen receptor modulators and uses thereof. Described herein are compounds that are androgen receptor modulators. Also ...
  http://patents.com/isd-20161101-p84.html
*  Abarelix - Wikipedia
Gonadotropin-releasing hormone receptor § Antagonists "Abarelix". PubChem. 2017-07-29. Drugs.com: Abarelix Boccon-Gibod, L.; ... Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) ... Van Der Meulen, E.; Persson, B. -E. (2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate ...
  https://en.wikipedia.org/wiki/Abarelix
*  CJU International - The Canadian Journal of Urology
Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix 2016; 23(1): 8179 - 8183 ... Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix 2016; 23(1): 8179 - 8183 ... A and its receptor in clinically localized prostate cancer: a prospective evaluatio 2008; 15(5): 4257 - 4262. ...
  http://canjurol.com/cumulative?CIOption=1
*  Ganirelix - Wikipedia
Gonadotropin-releasing hormone receptor § Antagonists European Medicines Agency. "Orgalutran". Retrieved 11 May 2012. Oberyé, J ... is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted ... Ganierlix is a synthetic peptide that works as an antagonist against gonadotropin-releasing hormone (GnRH) ("Ganirelix acetate ... This is avoided when using GnRH antagonists such as ganirelix. The success of ganirelix in reproductive therapy has been shown ...
  https://en.wikipedia.org/wiki/Ganirelix
*  ANTI-INFLAMMATORY AND ANTIOXIDANT COSMETIC COMPOSITION CONTAINING GREEN TEA POLYSACCHARIDE AND TRICHOLOMA MATSUTAKE EXTRACT -...
Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases. January, 2007. De Roux et al. ... and it targets arylhydrocarbon receptor (AhR) present in keratinocytes. It is known that this receptor is activated by ... METHODS FOR PROTECTING AND REGENERATING BONE MARROW USING CXCR3 AGONISTS AND ANTAGONISTS. April, 2010. Han et al. ... Aryl Hydrocarbon Receptor, AhR) Caused by Automobile Exhaust Gas. 2-1: Preparation of Automobile Exhaust Gas Sample ...
  http://www.freepatentsonline.com/y2011/0097356.html
*  Elagolix - Wikipedia
Gonadotropin-releasing hormone receptor § Antagonists List of investigational hormonal agents § GnRH/gonadotropins Ezzati, ... non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) which is under development for ... a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor". J. Med. Chem. 51 (23 ... "Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin- ...
  https://en.wikipedia.org/wiki/Elagolix
*  Gonadotropin-releasing hormone receptor - Wikipedia
GnRH antagonists block the receptor and inhibit gonadotropin release. GnRHRs are further regulated by the presence of sex ... The gonadotropin-releasing hormone receptor (GnRHR), also known as the luteinizing hormone releasing hormone receptor (LHRHR), ... is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family. It is the receptor of gonadotropin-releasing ... "The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane ...
  https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_receptor
*  Degarelix - Wikipedia
Gonadotropin-releasing hormone receptor § Antagonists Princivalle M, Broqua P, White R, et al (March 2007). Rapid suppression ... GnRH antagonists (receptor blockers) such as degarelix are a new type of hormonal therapy for prostate cancer. These agents are ... GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible binding blocks ... Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland ...
  https://en.wikipedia.org/wiki/Degarelix
*  Decoding neurohormone pulse frequency by convergent signalling modules | Biochemical Society Transactions
2010) Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists ... 2000) Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends ... 2006) Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors: receptor-specific activation mechanisms and ... gonadotropin-releasing hormone; GnRHR, GnRH receptor; GSU, gonadotropin subunit; LH, luteinizing hormone; MAPK, mitogen- ...
  http://www.biochemsoctrans.org/content/40/1/273
*  17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE - Patent application
Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists. 2016-01-07. Substituted ... Moreover, some interesting novel compounds act as antagonists for the mineralcorticoid receptor. [0036]Novel derivatives having ... 0006]The object of the present invention is to make available compounds which have strong binding to the gestagen receptor. ... On account of its comparatively low affinity for the gestagen receptor and its comparatively high ovulation-inhibiting dose, ...
  http://www.patentsencyclopedia.com/app/20100292184
*  CAS 214766-78-6 Degarelix acetate - BOC Sciences
Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III ... Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) ... PURPOSE: We assessed the cardiovascular safety profile of degarelix, a new gonadotropin-releasing hormone antagonist. ... Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer. ...
  https://www.bocsci.com/degarelix-acetate-cas-214766-78-6-item-84-465293.html
*  Degarelix (Firmagon) | HemOnc.org - A Hematology Oncology Wiki
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, ...
  https://hemonc.org/wiki/Degarelix_
*  PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS CONTAINING REBAMIPIDE AS AN ACTIVE INGREDIENT ...
Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the ... a H2-receptor antagonist (e.g., cimetidine, ranitidine, etc), and/or a proton pump inhibitor (e.g., omeprazole) are also co- ...
  http://www.patentsencyclopedia.com/app/20130065920
*  Hypothalamic control of neonatal T surge | Philosophical Transactions of the Royal Society B: Biological Sciences
Experiments in monkeys using a GnRH receptor antagonist to block endogenous GnRH-dependent gonadotropin secretion clearly ... The GnRH receptor antagonist caused a modest approximately 25% reduction in LH levels 60 min following birth compared with ... Peripheral administration of the GnRH receptor antagonist, Antide, on days 0, 3, 7, and then weekly from birth to 98 days of ... However, one study using GnRH receptor antagonists to probe the role of GnRH signalling in the neonatal testosterone surge has ...
  http://rstb.royalsocietypublishing.org/content/371/1688/20150115
*  FDA Approves Degarelix For Advanced Prostate Cancer Treatment | EmaxHealth
... a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate ... "Use of a GnRH receptor antagonist is a highly efficient way to stop the production of testosterone," said Neal Shore, MD, FACS ... Degarelix is the only GnRH receptor antagonist approved by the FDA for the treatment of hormonally-sensitive advanced prostate ... Now prostate cancer can be treated with immediate inhibition of the GnRH receptors, inducing rapid reduction of testosterone to ...
  https://www.emaxhealth.com/2/33/28006/fda-approves-degarelix-advanced-prostate-cancer-treatment.html
*  Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometr... ( Post-Treatment...
... orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. ... "Additionally, we are seeing for the first time an oral GnRH antagonist with a rapid and sustained symptom reduction during ...
  http://www.bio-medicine.org/medicine-news-1/Neurocrine-Announces-Full-Year-Results-from-603-Study--28Petal-Study-29-of-Elagolix-for-Treatment-of-Endometriosis-Pain-46253-1/